PHARMACOKINETICS OF PROSTAGLANDIN E1 AND ITS MAIN METABOLITES AFTER INTRACAVERNOUS INJECTION AND SHORT-TERM INFUSION OF PROSTAGLANDIN E1 IN PATIENTS WITH ERECTILE DYSFUNCTION

Abstract

No AccessJournal of UrologyClinical Urology: Original Articles1 Oct 1997PHARMACOKINETICS OF PROSTAGLANDIN E1 AND ITS MAIN METABOLITES AFTER INTRACAVERNOUS INJECTION AND SHORT-TERM INFUSION OF PROSTAGLANDIN E1 IN PATIENTS WITH ERECTILE DYSFUNCTION Willi Cawello, Horst Schweer, Bruno Dietrich, Hannsjorg Wilhelm Seyberth, Detlef Albrecht, Alanna Fox, and Horst Hohmuth Willi CawelloWilli Cawello , Horst SchweerHorst Schweer , Bruno DietrichBruno Dietrich , Hannsjorg Wilhelm SeyberthHannsjorg Wilhelm Seyberth , Detlef AlbrechtDetlef Albrecht , Alanna FoxAlanna Fox , and Horst HohmuthHorst Hohmuth View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)64226-5AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Alprostadil (prostaglandin E1) is the preferred monotherapy for intracavernous injection in the diagnosis and treatment of erectile dysfunction. Our study was designed to evaluate whether there is a difference in the pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection or short-term intravenous infusion. In addition, we also investigated the influence of the erectile response on prostaglandin E1 kinetics after intracavernous injection. Materials and Methods: A total of 24 patients with erectile dysfunction received, in a randomized order at an interval of 5 hours, an intracavernous injection or a 30-minute intravenous infusion of 20 micro g. of alprostadil alfadex (prostaglandin E1). Venous blood samples were obtained 5 minutes before and at various times after the applications. We used highly sensitive gas chromatography/double-mass spectrometry method to measure prostaglandin E1 and its metabolites in plasma. Results: We demonstrated the presence of relevant systemic blood levels of prostaglandin E1 and its metabolites immediately after intracavernous injection. We found significantly lower systemic prostaglandin E1 concentrations between 7 and 20 minutes after intracavernous injection in patients with an erectile response compared with those without. Conclusions: We found significant systemic concentrations of prostaglandin E1 and its metabolites after intracavernous injection. The systemic presence did not lead to significant changes in vital signs. References 1 : Studies on male sexual impotence. Report 18. Therapeutic trial with prostaglandin E1 for organic impotence. Nippon Hinyokika Gakkai Zasshi1986; 77: 954. Google Scholar 2 : Intracavernous injection of prostaglandin E1 in impotent men.. J. Urol.1988; 140: 66. Abstract, Google Scholar 3 : Intracavernous self-injection of prostaglandin E1 in the therapy of erectile dysfunction.. VASA1989; 28: 50. Google Scholar 4 : Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction.. Brit. J. Clin. Pharmacol.1989; 28: 567. Google Scholar 5 : Pharmacological erection program using prostaglandin E1.. J. Urol.1991; 146: 786. Abstract, Google Scholar 6 : Prostaglandin-15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated penile erection.. Brit. J. Urol.1989; 64: 180. Google Scholar 7 : Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum.. J. Urol.1994; 151: 1227. Abstract, Google Scholar 8 : Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.. Eur. J. Clin. Pharmacol.1994; 46: 275. Google Scholar 9 : Intracavernous Pharmaco Testing. Impotence-Diagnostic and Therapy. Edited by . Stuttgart: Georg Thieme Verlag1989. Google Scholar 10 : Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry.. Biol. Mass. Spectr.1994; 23: 165. Google Scholar 11 : Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.. Brit. J. Clin. Pharmacol.1995; 40: 273. Google Scholar 12 : Mechanism of venous occlusion during canine penile erection: an anatomic demonstration.. J. Urol.1987; 137: 163. Abstract, Google Scholar 13 : Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.. Urology1991; 37: 516. Google Scholar 14 : Papaverine hydrochloride in peripheral blood and the degree of penile erection.. J. Urol.1990; 143: 1135. Abstract, Google Scholar 15 : Moxisylyte plasma kinetics in humans after intracavernous administration.. Biopharmaceut. Drug Dispos.1992; 13: 671. Google Scholar 16 : Systemic pharmacokinetics of papaverine and phentolamine: comparison of intravenous and intracavernous application.. Int. J. Impot. Res.1990; 2: 247. Google Scholar 17 : The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.. J. Urol.1996; 155: 802. Abstract, Google Scholar From the Schwarz Pharma AG, Monheim am Rhein, Childrens Hospital, University of Marburg, Marburg, L.A.B. GmbH & Co, Neu-Ulm, and Urological Office, Ulm, Germany.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 158Issue 4October 1997Page: 1403-1407 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information Willi Cawello More articles by this author Horst Schweer More articles by this author Bruno Dietrich More articles by this author Hannsjorg Wilhelm Seyberth More articles by this author Detlef Albrecht More articles by this author Alanna Fox More articles by this author Horst Hohmuth More articles by this author Expand All Advertisement PDF downloadLoading ...